Form 4 Tracker
Benjamin Hohl

CHIEF FINANCIAL OFFICER · 3 filings · Latest: Jun 17, 2026

Enliven Therapeutics, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
ELVN
Benjamin HohlCHIEF FINANCIAL OFFICERJun 17, 2026
Sale
$43.806,018$263.6K51,000
ELVN
Benjamin HohlCHIEF FINANCIAL OFFICERJun 17, 2026
Option Exercise
$2.486,018$14.9K57,018
ELVN
Hohl BenjaminJun 17, 2026
Proposed Sale
$42.5518,054$768.2K
ELVN
Benjamin HohlCHIEF FINANCIAL OFFICERMar 6, 2026
Sale
$29.5810,000$295.8K51,000
ELVN
Hohl BenjaminMar 6, 2026
Proposed Sale
$29.2910,000$292.9K
ELVN
Hohl BenjaminSep 29, 2025
Proposed Sale
$20.014,500$90.0K
ELVN
Hohl BenjaminAug 27, 2025
Proposed Sale
$20.325,250$106.7K
ELVN
Hohl BenjaminJul 28, 2025
Proposed Sale
$21.204,250$90.1K
ELVN
Hohl BenjaminJun 27, 2025
Proposed Sale
$21.524,250$91.5K
ELVN
Hohl BenjaminJun 13, 2025
Proposed Sale
$19.993,000$60.0K
ELVN
Hohl BenjaminMay 27, 2025
Proposed Sale
$16.403,250$53.3K
ELVN
Hohl BenjaminMar 27, 2025
Proposed Sale
$20.584,250$87.5K
ELVN
Hohl BenjaminFeb 27, 2025
Proposed Sale
$20.284,250$86.2K
ELVN
Hohl BenjaminJan 27, 2025
Proposed Sale
$21.864,250$92.9K
ELVN
Hohl BenjaminJan 3, 2025
Proposed Sale
$23.901,000$23.9K
ELVN
Hohl BenjaminDec 27, 2024
Proposed Sale
$22.714,250$96.5K
ELVN
Hohl BenjaminOct 18, 2024
Proposed Sale
$28.0213,000$364.3K
ELVN
Hohl BenjaminOct 1, 2024
Proposed Sale
$25.5412,009$306.7K
ELVN
Hohl BenjaminSep 30, 2024
Proposed Sale
$24.13491$11.8K
ELVN
Hohl BenjaminApr 28, 2025
Proposed Sale
$18.213,250$59.2K